Positron emission tomography (PET), the imaging of pharmaceuticals labeled with positronemitting radionuclides, is a rapidly growing modality for the diagnosis and management of cancer. PET yields high-quality images characterizing substrate metabolism, cellular proliferation, receptor density, and other parameters that can be used to identify cancer and evaluate its response to therapies. The technique mainly utilized in cancer management is FDG-PET, which exploits the abnormal glucose metabolism of cancer cells first characterized by Warburg. We discuss the principles of PET, the currently available instrumentation and radiopharmaceuticals, the efficacy of FDG-PET in the management of cancer, and the prospects for near-term advances in cancer using PET.
Introduction
Positron emission tomography (PET) is now an important tool for the diagnosis and management of cancer. We will outline the scientific basis of this technique, describe the state of the art of PET technology, discuss the efficacy of currently available methods in cancer, and review current developments that may lead to advances in cancer imaging.
What is PET?
Positron emission tomography (PET) is tomographic imaging of positron emitting radionuclides. It exploits the annihilation of positrons and electrons to simultaneous back-to-back 511 keV photons, to achieve the nuclear-imaging analog of x-ray computed tomography (CT). The positron is the positively charged antiparticle of the electron. Unstable nuclei that are proton-rich may decay by positron (β + ) emission, (Z, A) → (Z-1, A) + β + + ν e , just as unstable neutron-rich nuclei decay by electron (β -) emission, (Z, A) → (Z+1, A) + β -+ν e . (They may also decay by electron capture.) In the decay of a positron-emitting radionuclide, the positron comes to rest within several mm and interacts with an atomic electron, yielding two photons that travel in (nearly) opposite directions, each with an energy of 511 keV, as shown in Figure 1 . By detecting these photons in coincidence (within several ns), the projection data required for tomographic reconstruction are obtained. The intrinsic resolution of PET is limited by the positron range, which increases rapidly with positron energy (see Table I ), and the small noncollinearity of the annihilation photons (1). For the current generation of scanners, which are capable of an imaging resolution of < 5 mm full width at half maximum (FWHM), tracers labeled with 15 O, 62 Cu, 82 Rb, and 94m Tc lead to degraded spatial resolution because of high β + energy.
Just as CT improves on planar radiography, PET imaging has significant advantages over conventional scintigraphy and single photon emission com-puted tomography (SPECT). PET images do not suffer from differential magnification and other artifacts, contain fewer scattered photons, are corrected for attenuation, and generally have better spatial resolution and contrast than single-photon images. PET is auto-collimating, not requiring the heavy-metal collimators required for image formation in planar and SPECT imaging, resulting in a much greater sensitivity. Part of the sensitivity gain with respect to planar imaging is lost because of the statistical cost of tomographic reconstruction (2).
Probably the most important feature of PET is that the positron-emitting radionuclides include 11 C, 13 N, 15 O, and 18 F, plus numerous other nuclides with decay times suitable for imaging, as shown in Table I . Carbon, nitrogen or oxygen are found in all biological molecules, which facilitates molecular imaging. We will discuss the requirements for good tracers below.
PET Technology
The central elements of PET technology for cancer are image formation and tracer design and synthesis.
The PET Scanner
A PET scanner is an array of detectors for 511 keV photons with the following characteristics:
Geometry
The scanner geometry is designed to capture a large fraction of the photon pairs resulting from annihilations in the patient. Most scanners are stationary cylindrical arrays of individual scintillation detectors multiplexed to photomultipliers. For adequate uniformity of response and geometrical efficiency, the cylinder inner diameter should be at least 70 cm, and its length at least 15 cm. The intrinsic spatial resolution of PET is >1 mm FWHM, depending upon the radioactive label. Current clinical scanners are designed to achieve spatial resolutions of 3 to 5 mm FWHM, which requires that the transverse dimensions of individual detectors be approximately that size (see reference 2 for details).
Thus a scanner has about 20,000 individual detectors and several hundred individual photomultipliers. Position-sensitive photomultipliers offer a design improvement, which is currently implemented in animal scanners (4).
Another approach to scanner design is an array of panel scintillators, either planar or curved, each viewed by a relatively small number of photomultipliers using Anger logic. These scanners were initially sodium iodide (NaI) based and thus less expensive because of reduced detector cost. They offer adequate sensitivity by virtue of being long axially, by accepting Compton as well as photopeak counts, and by utilizing highly oblique coincidence pairs. They suffer from high pulse-pileup, random-coincidence and scatter backgrounds, and the data pose a more difficult reconstruction problem than for the cylindrical geometry. However, a recent report describes a lutetium orthosilicate (LSO) scanner (5) constructed of five panels, each 37 cm (transaxial) by 53 cm (axial), which is extremely sensitive with good imaging properties, due to the superior properties of LSO.
Detectors
While PET has the property, unlike single-photon scintigraphy, of having a unique photon energy, 511 keV, the demands on detectors are severe. High stopping power and large photofraction for annihilation photons is essential, since the coincidence efficiency is the square of the detector photopeak efficiency ε. Fast detectors are required to minimize accidental coincidences and pulse pileup. Good energy resolution is important for scatter rejection, requiring, for scintillators, high light output. While the first scanners used sodium iodide (NaI), despite its long decay time and modest stopping power, bismuth germanate (BGO) Figure 1: After its emission in the decay of 11 C to 11 B, the e + is scattered repeatedly before coming to rest within approximately 2 mm. It then annihilates with an atomic electron, producing two 511 keV photons at approximately 180º.
quickly became the scintillator of choice. LSO is the best currently available scintillator, with high stopping power, high light output, and short decay time. The stopping power and timing requirements of PET make it unlikely that semiconductor x-ray diodes will be practical, however, the use of scintillators with avalanche photodiodes or other fast visiblelight detectors in lieu of photomultipliers is possible.
PET-CT
Nearly all PET scanners perform transmission CT of the patient using an external 511 keV photon source and the scanner detectors; the data are used to correct for photon attenuation in the body. Attenuation correction is particularly important in cancer imaging, since the non-correspondence of nonattenuation-corrected projections causes severe artifacts, which can obscure lesions or cause false positive scans. However the transmission images have the modest spatial resolution of the PET system and are statistically poor. PET scanners are now offered with diagnostic X-ray CT capability. The CT data are extrapolated to 511 keV, and used to correct the emission scan for photon attenuation. They also provide an effectively coregistered set of CT images for direct comparison, allowing superposition of anatomical and physiological images. The latter capability is particularly valuable for characterizing small lesions in cancer patients. A particular problem for attenuation correction, using either an external source or CT, is patient movement between the emission and transmission scans, causing artifacts.
Imaging by Anger Cameras
The effectiveness of PET has motivated the adaptation of single photon imaging systems for PET tracers. While the performance of these systems is much poorer than that of dedicated systems, certain applications may be practical. There are two approaches:
Coincidence Imaging
This appellation is given to a dual back-to-back Anger camera system that can be operated in coincidence mode, so that collimators are not required. It performs a 180 degree rotation around the patient, in order to obtain the required lines of response (LOR). In these systems the NaI thickness is set to 3/8" or 1/2" compared to the 1/4" which is generally optimal for 99m Tc imaging, in order to achieve higher sensitivity. Spatial resolutions in the 5mm to 1cm FWHM range have been obtained. The sensitivities of these systems are much smaller than those of dedicated PET systems. These systems have been used effectively in cancer, but have diminished ability to detect small and faint lesions. Difficulties in precise alignment of the independent rotating camera heads are a source of artifacts.
SPECT
SPECT can be performed using either a single-headed or multiple-headed camera. A 511 keV collimator is used, which significantly diminishes the resolution and sensitivity compared to a PET scanner. This technique is suited to cardiac scanning, where the target is a large-dimension intense target.
The physics and engineering of PET scanners is fully discussed elsewhere (2).
Tracers
A PET tracer is a biomolecule labeled with a positron-emitting nuclide that has suitable physiological and imaging characteristics. Many have been developed. Tracers must be substrates for physiological processes. With the exception of exchangeable perfusion tracers such as 15 O water, they must also localize in the tissues of interest. Most natural biomolecules don't do this, with exceptions, such as iodide (thyroid) and fluoride (bone). Generally it is aphysiological for a molecule to localize and bind. For example, nutrient molecules such as sugars, amino acids, and fatty acids are rapidly metabolized. Neurotransmitters rapidly bind and unbind with receptors to maintain the dynamic function of neuronal circuits. Thus useful tracers are often analogs of endogenous molecules, for example deoxyglucose (DG), which competes with glucose for transport and phosphorylation, and then is trapped as DG-6-P within cells, facilitating imaging. Similarly, neuroactive drugs such as raclopride and cocaine, which respectively have much higher specific affinities for dopamine D2 binding and dopamine reuptake than dopamine itself, are effective PET ligands.
Some critical features of a PET tracer are:
Localization, metabolism, and the circulation of metabolites: A compound that is metabolized prior to reaching its target tissue cannot be an effective tracer. The tracer should concentrate in cells by a specific mechanism, and should not give rise to labeled recirculating metabolites that bind nonspecifically in tissues of interest.
Appropriate biological and physical half-life: The tracer must be available long enough to specifically bind to the target tissue, and must remain bound until after background activity has cleared. A long physical half-life leads to excessive radiation to the patient. The biological time scales for the uptake of metabolic tracers by cancers, and for clearance of non-specifically bound tracers, are tens of minutes to hours. Thus the appropriate physical half-life of the label is at least that long. 18 F (110 min) is about right but 11 C (20 min) is usually too short-lived. If PET cancer tracers are to be made available for routine use, they must certainly be flu-orine labeled to provide the capability of distribution to centers without cyclotrons. 18 F is now made in large quantities at low cost, and several important 18 F-labeled tracers are chemically stable for many hours.
High specific activity: Specific activity (SA) is a measure of the fraction of the mass quantity of a tracer that is radioactively labeled, and is measured in Ci/µmole or equivalent. Tracers labeled with 11 C have smaller SA than those labeled with 18 F, because of the shorter half-life of 11 C and the large quantity of carbon in the environment. SA is important when the capacity of the target system is small, and when small quantities of pharmaceutical have pharmacological effects, such as in some CNS neurotransmitter systems. The tracers used for cancer scanning are generally metabolic substrates, where the body's capacity is very large. However, SA is a consideration for tracers that target specific receptors on cell surfaces.
Transport by blood-brain barrier, lipophilicity: For tracers used in brain scanning, penetration of the blood-brain barrier (BBB) is generally mandatory, although some tracers used for this purpose, such as TcO 4 -, detect only those brain abnormalities that cause breakdown of the BBB. Tracer molecules must generally be small and highly lipophilic to penetrate the brain, with the exception of those, like FDG, which are transported by specific mechanisms.
Tracer Production
The synthesis of fluorine-, carbon-, nitrogen-and oxygenlabeled tracers requires an accelerator capable of delivering 10 MeV protons to a target, plus shielded synthetic facilities. Higher energy machines, and those that accelerate deuterons, provide capabilities for additional isotopes and production reactions, that don't require isotopically enriched target nuclei. The cyclotron is the standard for PET although electrostatic accelerators are used effectively. Small cyclotrons and automated synthetic systems are commercially available for routine production of a large number of tracers, permitting a broad clinical and clinical research program without a dedicated chemistry facility. Table III gives the commonly used production reactions for PET isotopes. For isotopes of C, O, N, and F, gas and liquid targets are required. For longer-lived isotopes, such as 64 Cu and 124 I, solid targets may be bombarded and subsequently refined. The available generator systems, 62 Zn-62 Cu (9.74 min), 82 Sr-82 Rb (75 sec), and 68 Ge-68 Ga (67.6 min) have not yet been found useful for cancer imaging. 94m Tc may be useful for exploiting the 99m Tc chemistry developed for single-photon imaging.
The cross section for 18 F production is very large, and multicurie quantities of 18 F are made in a single 1-2 h bombardment (6). Depending on the tracer, the synthetic yield is 20-60%, so a full day of scanning can be supported from one or two bombardments, and tracers can be distributed locally. High-demand 18 F-labeled tracers are offered commercially, allowing PET centers to operate without their own cyclotrons and synthetic facilities. 11 C synthetic yields are typically smaller, with the short halflife and low specific activity precluding multiple studies from a single synthetic run.
The very large quantity of activity handled in tracer synthesis requires a fully remote-controlled, well-shielded apparatus and strict attention to radiation safety. The relatively short half-lives of the tracers nearly eliminates the problem of radioactive waste disposal.
Functional Imaging in Cancer
The purpose of imaging in cancer is multifold.
Diagnosis
Imaging is useful in diagnosing anatomical findings that are suspicious for cancer, for example, a lung nodule, an enlarged lymph node, or an abdominal mass.
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Mandelkern and Raines C-choline phospholipid synthesis: brain and prostate cancer 11 C-raclopride dopamine D 2 binding: psychiatric illnesses 11 C-methionine amino acid uptake: brain cancer Imaging is used to search for cancers that are suspected on the basis of non-specific findings, such as constitutional signs and symptoms, including fever and unexplained weight loss, the presence of an elevated tumor marker, or a neurological deficit.
Imaging is used to locate a primary cancer after metastatic disease is diagnosed, often in head and neck, lung, and colorectal cancers.
Staging
After a diagnosis of cancer is made, it is important to determine the extent and distribution of disease, in order to plan appropriate treatment.
Treatment Evaluation
During and after treatment it is important to evaluate the patient, so that treatment can be appropriately modified.
Evaluation for Recurrence
A successfully treated patient should be periodically reevaluated, so that recurrence may be promptly restaged and treated. PET is useful in the presence of rising tumor markers such as carcinoembryonic antigen (CEA) or thyroglobulin, as it provides a sensitive whole-body survey.
While these indications differ somewhat in their requirements, an imaging method for cancer must have the ability to distinguish cancer from normal tissue, and from tissue that is inflamed, infected, in the process of healing, or fibrosed. Thus it must have functional as well as anatomical imaging capability.
A modality is characterized by its imaging characteristics and also by the contrast mechanism it exploits. We have a number of excellent imaging methods that are used effectively in cancer diagnosis and management, including mammography, CT, MRI, and ultrasound, as well as nuclear imaging. CT, with or without contrast agents, is used effectively in many malignancies, exploiting the high contrast between air, soft tissue and bone, and that derived from the introduction of iodine or barium in anatomical spaces and in blood and lymphatic channels. MRI is effective in central nervous system lesions and where subtle soft-tissue distinctions are important, such as in the retroperitoneum, head and neck, and for assessing soft-tissue sarcomas, malignant infiltration of vessels, and detecting hemorrhage. Here the T1 and T2 relaxation times produce contrast, partly by their sensitivity to the concentration of free water. Ultrasound detects surfaces between different tissues, and is good for staging endometrial cancer and distinguishing cysts from solid masses. These techniques are mainly anatomical although each delivers some physiological information. Their spatial resolutions are 1 mm or smaller. The major shortcoming of these methods is insensitivity to the metabolic processes of tissues. Conventional imaging (CI) has difficulty distinguishing an active malignancy from a benign lesion, and from pre-and post-therapeutic changes including scarring, inflammation, and necrosis. It is in this regard that nuclear imaging contributes, since our capability for synthesizing tracers for physiological processes provides a great many mechanisms for contrast production. These include tissue perfusion, glucose and fatty acid metabolism, protein and nucleotide synthesis, hypoxia, and the presence of specific receptors of various types. Glucose is transported into cells, phosphorylated by hexokinase, and then either metabolized to CO 2 and H 2 O (given aerobic conditions) or converted to glycogen. 18 FDG is transported and phosphorylated in competition with glucose, but can neither be further metabolized nor converted to glycogen. Although PET is inferior in spatial resolution to CI, it provides physiological (functional) data. These include tissue metabolic rates, measures of tissue hypoxia and the densities of specific surface receptors in cell membranes. Since functional changes predate anatomical ones, such data may facilitate early diagnosis. Biochemical data may aid in the classification of a lesion. Functional information can aid in the prompt assessment of a therapeutic response. The data provided by PET are best assessed in combination with anatomical data, as the locations of phtsiological changes can significantly alter their interpretations. A promising methodology for simultaneous assessment of functional and anatomical data is the relatively new technology of PET-CT hybrid imaging.
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PET Methods in Cancer
Indications
The PET tracer primarily utilized in oncological PET, and the only one currently reimbursed for in cancer, is the glucose analog 2-18 F-fluoro-2-deoxy-D-glucose (FDG 
FDG PET
Mechanism
In 1924, Warburg showed that the metabolism of glucose is altered in tumor cells (7). These cells demonstrate a high excretion of lactic acid, even in aerobic conditions, showing that they cannot fully oxidize glucose.
More recent work has shown that there is increased and unregulated transport of glucose in cancer cells, due to pas-sive transport through the transformed membrane (8).
Transformed cells also demonstrate an increase in the expression of glucose transporter proteins (9, 10).
Seven glucose transporters have been identified (GLUT 1-7) (11, 12), of which GLUT 2 and GLUT 4 are insulin-dependent. Increased expression of GLUT 1 and GLUT 3 (noninsulin-dependent) has been observed in hepatocellular carcinoma (13) and in brain tumors (14). While cultured fibroblasts transfected with src or ras oncogenes show increases in glucose uptake, glucose transporter proteins, and hexokinase, those transformed by the myc oncogene do not show increases (10). Thus the origin of a tumor determines glucose uptake.
After glucose enters a normal cell, it is phosphorylated to glucose-6-phosphate (G6P) by hexokinase. G6P is the substrate for G6P isomerase, giving fructose-6-phosphate (F6P), which is then further metabolized by the glycolytic system. 2-deoxyglucose (2DG) was introduced by Sokoloff (15) for autoradiographic study of cerebral glucose utilization. It is transported by GLUTs and phosphorylated by hexokinase to 2DG6P; however, the isomerase reaction does not occur and 2DG6P is effectively trapped in the cell, as shown in Figure  2 . FDG is similarly trapped in cells, making it, like 2DG, useful for evaluating cellular uptake of glucose. The kinetics of glucose, 2DG, and FDG are not the same, and the relationships among these have been obtained in the brain, for the purpose of quantitative studies of cerebral glucose metabolic rates. While glucose is not normally excreted in the urine, DG and FDG are, causing difficulties in evaluating malignancies of the urinary system and nearby tissues.
Attributes and Limitations
FDG-PET has been shown to be highly effective in cancer. Most cancers take up FDG avidly, its biological and physical half-lives are appropriate for clinical use, it is inexpensive to manufacture reliably, and is chemically stable, facilitating distribution. However, FDG-PET has the following limitations:
Sensitivity: FDG-PET is highly sensitive in many common cancers. However, it is less sensitive in lesions such as bronchioalveolar and hepatocellular carcinomas, and relatively insensitive in prostate cancer, papillary, follicular and medullary thyroid carcinomas, carcinoid, pheochromocytoma, teratoma, and generally in highly differentiated cancers. Physiological uptake of tracer reduces sensitivity in certain anatomical regions, such as the brain, the vicinity of the heart, and the genitourinary system.
Specificity:
There are many tissues that demonstrate significant physiological FDG uptake. FDG is excreted in the urinary system. Uptake is highly variable in the salivary glands, tonsils, oropharynx, nasopharynx, larynx, and muscles in the head and neck (16). Despite fasting, the heart is often intense. Muscle uptake reflects physical activity and/or elevated insulin levels, and the gastrointestinal tract (especially the cecum and stomach) is often intensely hypermetabolic. Inflammatory and infectious lesions can be highly FDG-avid, for example in pulmonary sarcoidosis and tuberculosis. Some benign tumors, such as functioning pituitary adenomas, demonstrate intense uptake, as shown in Figure 3 . Surgical changes, radiation therapy, and degenerative lesions can also produce false-positive scans.
FDG-PET Procedure
FDG-PET is easy to perform. To facilitate FDG uptake in cancer cells while maintaining low background uptake, the patient's recent food intake should be restricted, to minimize the competition between FDG and endogenous glucose, his/her insulin level should be low, to avoid excessive uptake by striated muscle, heart, and liver, and physical activity should be controlled, again to minimize muscle uptake. In particular, fasting usually causes the heart to switch to lipid metabolism. The absence of cardiac uptake greatly improves sensitivity for lesions in the chest. Low blood-sugar level is not a guarantee of low cardiac and muscle uptake, or of adequate brain uptake. The latter is a particular problem in diabetic patients, who have poor brain uptake despite reduction of serum glucose. The patient should be well hydrated to dilute excreted tracer in the urinary system, which improves image quality, and minimizes bladder irradiation. An overnight fast is desirable for patients scanned in the morning. Afternoon patients are often allowed a light breakfast. After intravenous injection of 5 to 20 mCi of FDG, the patient is asked to rest quietly for at least 45 minutes before scanning. In a typical procedure, the patient is scanned sequentially in overlapping bed positions for roughly 5 minutes/position, for an overall time of 30 to 60 minutes. Measures taken to improve imaging when indicated include mild sedation to reduce muscle uptake, the use of diuretics, and urinary bladder irrigation to reduce activity in the urinary tract (17), as well as iso-osmotic cleansing of the colon (18). It has been shown that, compared to non-malignant lesions, FDG uptake in cancer increases with time after injection (19). Sequential delayed imaging can be useful in lesion discrimination.
Interpretation
Clinical interpretation of FDG-PET is generally done qualitatively. However quantitative measures of uptake have been introduced. Standardized uptake value (SUV) is a measure of uptake normalized to the injected dose and patient's body weight.
Although SUV is potentially useful in distinguishing malignant from benign lesions, especially in the lung, the variability and heterogeneity of uptake, and the interaction of scanner resolution with lesion size, are problems that have not been satisfactorily resolved.
Efficacy
We follow with a concise review of the effectiveness of FDG-PET in cancer management. Recent comprehensive reviews of the FDG-PET literature are those of Reske, Gambhir, . Individual studies are quoted when they add significantly to the results of meta-analyses. As indications are added, and the volume of cases increases, measures of efficacy change significantly, and in particular are determined for narrower disease categories, for example, separately for different histological classifications, and for diagnosis, staging, and follow-up. The quality of instrumentation is improving rapidly,
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Technology Metastatic disease is discussed with the primary cancer. FDG-PET has not been as thoroughly explored in pediatric tumors. Results when available are given with the corresponding adult cancers.
Brain
Because of the intense FDG uptake in normal brain gray matter, FDG-PET is relatively poor for identifying malignant brain lesions. There is significant overlap between SUV in tumors and that in contralateral normal brain (in both gray and white matter) (23). FDG uptake by primary CNS tumors is correlated with tumor grade (24, 25), and carries prognostic significance (26); the survival of patients with hypermetabolic tumors is significantly shorter than that of patients with hypometabolic tumors. From Gambhir (21), the mean sensitivity of FDG-PET for diagnosing intracranial cancers (by patient, 91 patient studies) is 89%, and the sensitivity/specificity for detecting recurrence of intracranial cancer (367 patient studies) is 79%/77%.
Head and Neck
The head and neck demonstrates highly variable and frequent- 
(a) (b)
ly intense normal FDG uptake in the mucosa, salivary glands, lymphatic tissues and muscles. In the primary staging of head and neck carcinomas, sensitivities range from 67% to 91%, and specificities from 82% to 100%. For residual or post-therapy head and neck malignancies, sensitivities range from 80% to 100%, and specificities from 81% to 100% (22). The timing of FDG-PET evaluation of head and neck cancers after radiation therapy is important, as post-radiation changes can lead to false positive results. A study of 44 symptomatic patients, who had received various therapeutic regimens (including radiotherapy in 42 patients) found a sensitivity/specificity of 96%/90% in those scanned greater than 12 weeks after completion of therapy, but 100%/25% in those evaluated earlier (27). In patients with a cervical lymph node metastasis and unknown primary tumor, FDG-PET identified the primary in 10-47% of cases (22). However, a recent study, using coregistered FDG-PET and MRI, accurately localized the primary tumor in 12 of 13 occult head and neck cases (28). Figure 6a is a FDG-PET scan of a patient with a primary cancer of the palate with regional metastatic lymph nodes.
Thyroid 123 I and 131 I whole-body scanning are useful for detecting recurrence in highly differentiated papillary and follicular thyroid carcinomas, where FDG-PET is not particularly sensitive. FDG-PET is useful in patients with elevated thyroglobulin and negative radioiodine imaging. Gambhir (21) gives a mean sensitivity/specificity (by patient, 640 patient studies) of 69%/89% for staging of thyroid cancers, and 73%/86% (by patient, 497 patient studies) for detecting recurrence.
Lung
Lung cancer is the most common indication for FDG-PET. Both small-cell and non-small-cell lung cancers usually show intense FDG uptake. Bronchioloalveolar carcinoma is less avid for FDG with a correspondingly smaller sensitivity (of 82% per Salman (29), based on 35 patients). Both acute pneumonias and chronic pulmonary infections, including tuberculosis, coccidiodomycosis, and histoplasmosis, can produce findings that are difficult to distinguish from cancer. The presence of inflammatory hilar and mediastinal nodes secondary to chronic lung disease is a source of false-positive findings. Pulmonary sarcoidosis often presents with extremely intense parenchymal and/or lymphatic FDG uptake, as shown in Figure 4a , a scan of a patient with colorectal cancer metastatic to the liver. For diagnosis of non-small-cell lung cancer, the overall sensitivity/specificity (by patient), based on 1108 patient studies, is 96%/73% (21). It is 83%/91% (4005 patient studies) for staging, 98%/92% (337 patient studies) for evaluating recurrence, and 94%/90% (270 patient studies) for evaluating response to therapy. Figure 5a is an example of a malignant single pulmonary nodule.
Two studies of pleural mesothelioma respectively reported a sensitivity/specificity of 91%/100% (by patient) in 28 patients (30), and 100%/89% (by lesion) in 18 patients (31).
In a study of 41 patients with cancer (34 with lung cancer) and adrenal lesions, Yun (32) found a sensitivity/specificity of 100%/94% for adrenal metastasis.
Breast
Breast cancer is highly FDG-avid. The weighted sensitivities/sensitivities compiled by Gambhir (21) are: for diagnosis (by patient, 318 patient studies) 91%/93%, for staging (2034 patient studies) 91%/88%, for recurrence (977 patient studies) 80%/85%, and for monitoring response (269 patient studies) 81%/96%.
Although sensitive to distant metastases and valuable in determining prognosis, FDG-PET clearly cannot detect all tumor-infiltrated nodes. It is useful for detecting recurrence and for identifying responders to chemotherapy. FDG uptake shows a characteristic flare response in responders to tamoxifen therapy. Figure 4b is a scan of a post-mastectomy patient who presented with a chest-wall recurrence.
Gastroesophageal
Although physiological uptake of FDG in the stomach is common, and esophagitis causes FDG uptake, FDG-PET is effective for detecting primary lesions as well as distant metastases, but poor at detecting locoregional metastases. Gambhir (21) gives a mean sensitivity for diagnosis (by patient, 168 patient studies) of 96%, and for staging (by patient, 545 patient studies) 73%/90%. In a series of 27 patients, Brucher (33) showed that, for squamous cell carcinoma of the esophagus, FDG-PET three weeks after the end of radiotherapy and chemotherapy can distinguish responders from nonresponders (sensitivity/specificity of 100%/55%). In a study of 41 patients with a suspicion of esophageal cancer recurrence, Flamen (34) found FDG-PET to be sensitive for both regional and distant recurrences (sensitivity/sensitivity 94%/82%).
For gastric cancer, Yeung (35) , in a series of 21 patients, found a sensitivity/specificity of 93%/100% for the primary lesion, but 22%/97% for intra-abdominal lymph node metastases. Couper (36) found, for 14 patients with esophageal and gastric cancer, that decrease in the FDG uptake of a tumor correlates with its response to chemotherapy. However some patients, whose tumors demonstrated decreases in FDG uptake after chemotherapy, did not show clinical improvement.
Colorectal
Physiological uptake of FDG in the large bowel is also common, especially in the vicinity of the cecum. Abdel-Nabi (37) found a sensitivity of 100% for primary intraluminal carcinomas in 48 patients with biopsy-proven disease, but only 29% for 14 patients with lymphatic metastases. Huebner (38) performed a meta-analysis for recurrent colorectal cancer, yielding a sensitivity/specificity (by patient) of 97%/76% for the whole body (281 patients), 96%/99% for hepatic involvement (393 patients), and 94%/98% for local and pelvic involvement (366 patients). Ruers (39) found, for 51 patients whose colorectal liver metastases were evaluated by histopathology or intraoperative ultrasound, a sensitivity of 14% for lesions < 1.5 cm, 84% for those between 1.5 cm and 3 cm, and 100% for those >3 cm. Figures 6b and 4a respectively are scans of patients with primary and metastatic (to the liver) colorectal cancer.
Liver and Biliary
Hepatocellular carcinoma is not especially FDG-avid. This feature, plus the heterogeneous uptake of FDG in normal liver and the high incidence of the tumor in patients with prior liver disease, causes the sensitivity of FDG-PET to be 50-57% (40, 41) .
In 8 patients with cholangiocarcinomas, Delbeke (40) reported 100% sensitivity.
The sensitivity of FDG PET for metastatic liver lesions varies significantly with the disease, and is discussed with the primary cancer.
Pancreatic
In 106 patients with pancreatic masses, who were suspected of having pancreatic cancer, Zimny (42) reported a sensitivity/ specificity of 85%/84%, with false negatives in hyperglycemic patients, and false positives in patients with acute or chronic active pancreatitis. For euglycemic patients, the sensitivity was 98% and the specificity 85%. A review by Zimny (43) gave a mean sensitivity of 92% and a mean specificity of 79%. For liver metastasis in 168 cases, Frohlich (44) reported the sensitivity by patients as 68%, that for lesions >1 cm as 97%, and that for lesions < 1 cm as 43%, with a specificity of 95%.
Kidney and Urinary Bladder
The presence of high concentrations of FDG in the renal pelvis, ureters and bladder creates difficulty in evaluating primary lesions and local spread of bladder and renal cancer, as well as small adrenal lesions. Attenuation-corrected PET, available routinely with the current generation of scanners, as well as PET-CT, are particularly helpful here, and have substantially improved the performance of FDG-PET.
In renal cell carcinoma, the literature contains little data on diagnosis of the primary cancer, although Ramdave (45) reported a sensitivity/specificity of 94%/94% in 17 patients. For regional nodes and distant metastases, Gambhir (21) reports the mean sensitivity/specificity (by patient, 101 patient studies) as 76%/100%.
For urinary bladder cancer, the available data mainly applies to lymph node staging, where Gambhir (21) reports a mean (by patient, 136 patient studies) of 76%/87%.
Wilms tumors accumulate FDG, but only a small series of cases have been reported, by Shulkin (46) .
Ovarian, Uterine, Cervical
In ovarian cancer, the sensitivity and specificity of FDG-PET are relatively low. Fenchel (47) reported a sensitivity/specificity of 58%/76% in 99 patients with asymptomatic adnexal masses. Hubner (48) , in 51 patients, reported 93%/82% for primary ovarian cancers and 83%/80% for all lesions. In the evaluation of 31 patients for recurrent epithelial ovarian cancer, Cho (49) found the sensitivity/specificity to be 45%/100%.
Cervical and uterine cancers tend to be FDG-avid. However these diseases have not been studied thoroughly with FDG-PET, partly because the presence of radioactivity in the bladder in non-attenuation-corrected scans produces confusing artifacts. However, with the newer scanners, and especially with PET-CT, additional data should be forthcoming.
In 35 patients with stage IB and II cervical cancer, Reinhardt (50) found a sensitivity/specificity of 91%/100%. In 27 patients with stage 1b to 4b cervical carcinomas, Narayan (51) found that FDG-PET detected all 24 residual macroscopic tumors, and had a (by patient) sensitivity/specificity of 83%/92% for pelvic disease, and a specificity of 92% for nodal involvement.
In 5 patients with uterine sarcoma, Umesaki (52) reported that FDG-PET identified all of the cancers.
In 34 women previously treated for endometrial carcinoma, Belhocine (53) found a sensitivity/specificity of 96%/78% for recurrence.
Testicular and Prostate
In a study of 50 patients with germ cell cancer, Cremerius (54) found that FDG-PET had a sensitivity/specificity of 87%/94% for metastasis. In 37 patients with clinical stage I and II testicular germ cell tumors, Albers (55) found that FDG-PET detected 7 of 10 metastatic lesions without false positives, but was insensitive to teratomas. Spermon (56) studied 38 patients after chemotherapy, and found that FDG-PET was relatively insensitive to teratomas.
Prostate carcinoma is generally not FDG-avid, although advanced aggressive disease tends to be more so. The proximity of the prostate to the urinary bladder is a further obstacle to prostate imaging with FDG. Effert (57) studied 48 patients with untreated prostate cancer and 16 with benign prostatic hypertrophy (BPH), and found low uptake of FDG in 81% of primary tumors, a lack of correlation between FDG accumulation and tumor grade or stage, and significant overlap between FDG uptake in BPH and that in cancer. Oyama (58) studied 44 patients with prostate cancer and 5 with BPH and found a sensitivity/specificity for the primary lesion of 64%/100%. Oyama (59) reported a sensitivity of 80% for abnormal accumulation of FDG in the prostates of 10 patients with relatively advanced disease.
For 13 patients with prostate cancer metastatic to bone, Yeh (60) reported that FDG-PET detected only 18% of the lesions seen on bone scan. 11 C-choline and 11 C-acetate are promising tracers for prostate cancer as discussed below, and illustrated in Figures 7 and 8 .
Muscle and Connective Tissue
In a series of 62 patients with 15 different types of soft-tissue sarcoma, Lucas (61) found the sensitivity/specificity for local recurrence to be 73.7%/94.3%, and that for detection of pulmonary metastases 86.7%/100%.
The intensity of FDG uptake by the tumor was correlated with the grade of malignancy, with higher-grade tumors demonstrating more intense uptake in areas of viable tumor than lowgrade or benign tumors. The studies of Nieweg (62) and Kole (63) showed that the calculated mean glucose metabolism rate is significantly correlated with histologic grade of malignancy in series of 17 and 18 patients, respectively.
Dimitrakopoulou-Strauss (64) evaluated 56 patients for softtissue sarcomas, of whom 39 had suspected recurrence, and 17 were suspected of having a primary tumor. Visual inspection resulted in a sensitivity of ~76% and a specificity of ~43%.
Bone
In osteogenic (OS) and Ewing's (ES) sarcomas, Aoki (65) and others have found significant overlap in the SUVs for these versus benign lesions. However in 37 patients with malignant bone lesions and 46 with benign ones, Dimitrakopoulou-Strauss (66) achieved a sensitivity/specificity of 76%/97%, by using a quantitative analysis that included SUV, kinetic parameters, and a measure of lesion inhomogeneity.
Franzius (67) reported that, in 38 patients with ES, the sensitivity/specificity (by patient) for primary osseous metas-tases was 100%/96%, but that in 32 patients with OS, FDG-PET identified none of the 5 patients with primary osseous metastases. Daldrup-Link (68) reported, in 39 patients (2 to 19 years old), that, in initial staging, the sensitivity of FDG-PET for osseous metastases from a variety of primary tumors was (by lesion) 90%, better than whole-body MR (82%) and bone scintigraphy (71%). FDG-PET detected 22 of 25 metastases from ES but missed the one metastasis from OS.
Franzius (69) reported that, in 21 patients with ES and 6 patients with OS, the (by patient) sensitivity/specificity for all sites of recurrence was 96%/81%, and that FDG-PET detected all of the osseous recurrences of OS. They speculated that in recurrent disease, OS is more aggressive, resulting in greater FDG uptake.
In a study of 33 pediatric patients with primary bone sarcomas (18 OS, 14 ES), Hawkins (70) reported that FDG-PET is predictive of an effective response to chemotherapy.
Schirrmeister (71) evaluated 28 patients with multiple myeloma and 15 patients with solitary plasmacytoma, observing increased tracer uptake in 38 of 41 known osteolytic bone lesions (sensitivity 92.7%) in 23 patients, and 71 bone lesions that were negative on radiographs in 14 patients. Twenty-six (36.6%) of these lesions were confirmed in ten patients. The sensitivity/specificity was quoted as 83.8-91.9%/ 83.3-100%.
Lymphoma
In Hodgkin's and non-Hodgkin's lymphomas, FDG-PET has been shown to be highly effective in staging, detecting recurrence, and in monitoring therapy. The compilation of Gambhir (21) gives a mean sensitivity/specificity (by patient) for staging of 90%/93%, based on 1796 patient studies, of 87%/93% (by patient) for detecting recurrence, based on 581 patient studies, and 90%/93% for monitoring response to therapy, based on 279 patient studies.
In untreated non-Hodgkin's lymphomas, high FDG uptake is associated with a high histologic grade of malignancy and a high proliferation rate. Figure 4c is an FDG-PET scan of a patient with widely disseminated non-Hodgkin's lymphoma. FDG uptake is low in indolent low-grade non-Hodgkin's lymphomas and FDG-PET is not an effective method in this group of diseases.
Endocrine
Neuroendocrine cancers such as carcinoid, pheochromocytoma, and medullary carcinoma of the thyroid are variably FDG-avid. In analogy to functioning thyroid carcinomas, highly differentiated tumors are more likely to take up tumor-specific tracers (see below), and less likely to take up FDG, and vice versa.
Hoegerle (72), in a study of 17 patients (92 lesions) with carcinoid tumors, found a sensitivity of 29% for FDG-PET, but a sensitivity of 65% for 18 F-FDOPA PET. Le Rest (73) studied 15 patients with metastatic neuroendocrine tumors (11 carcinoid tumors, 4 paragangliomas), and found that FDG-PET detected cancer in 11/15 (107 lesions), better than 111 In-[D-Phe1]-DTPAoctreotide and 123 I-metaiodobenzylguanidine (MIBG). Shulkin (74) , in 29 patients with pheochromocytomas, found a sensitivity of 72% (by patient), with more frequent accumulation of FDG in malignant lesions. Lesions that did not accumulate MIBG were more likely to accumulate FDG and vice versa.
Szakall (75), in 40 patients with elevated calcitonin levels after surgery for medullary carcinoma of the thyroid, found that FDG imaging was about twice as sensitive as CT/MRI for residual/recurrent tumor.
Shulkin (76) reported avid tumor uptake of FDG in 16 of 17 neuroblastoma patients, and showed that concentration is not dependent on type 1 catecholamine uptake (both MIBG-positive and negative lesions accumulate FDG). In 51 patients with high-risk neuroblastoma, Kushner (77) found that FDG-PET is better than MIBG and bone scan in identifying both soft tissue and extracranial skeletal metastases (normal brain uptake impairs detection of cranial vault lesions).
Melanoma
Melanoma is generally highly FDG-avid. The mean sensitivity/specificity for staging, based on 1327 patient studies (21), is 83%/91% (by patient). FDG-PET is widely used for staging, restaging, and preoperative planning in metastatic melanoma. It is particularly useful in areas where CT is weak such as lymph nodes, small bowel, and soft tissue. Acland (78) found that the sensitivity and specificity increase significantly with stage. FDG-PET cannot be relied upon, as for breast cancer, to identify small local nodal metastases (79). Figure 5b is an example of FDG-PET in widespread metastatic melanoma.
Other Tracers
Lipid Tracers (Choline and Acetate)
Choline and acetate are incorporated into lipids as well as metabolized, choline mainly in the liver and kidney, and acetate in the liver, spleen, and pancreas. The rationale for using these substrates as tracers is the expectation of significant cellular accumulation in cancers. Choline is a precursor of phosphorylcholine, which is incorporated into the phospholipids of the cell membrane. Phosphorus-31 magnetic resonance spectroscopy has demonstrated a significantly elevated level of phosphatidylcholine in a number of tumors, including prostate cancer (80). Acetate enters the bicarbonate pool. Neither 11 C-choline nor 11 C-acetate are excreted in the urine, taken up by normal brain tissue, or accumulate in inflammatory lesions. 11 C-choline accumulates in cancers of the head and neck, lung, esophagus, colon, ovarian, prostate, brain, and in mediastinal and pulmonary hilar metastatic lymph nodes (81, 82) . Prostate and brain cancers are of particular interest because of the poor performance of FDG in these lesions, and mediastinal and hilar adenopathy are of interest because of FDG uptake in inflammatory lesions in chronic lung disease. Figure 7 shows 11 C-choline and FDG scans in a patient with metastatic prostate cancer. In brain malignancies, there is a strong correlation between lesion grade and 11 C-choline uptake (83). 11 C-choline accumulates in malignant lymph nodes in metastatic prostate cancer, but not in bone lesions (84). Lack of urinary excretion facilitates the observation of 11 C-acetate uptake in renal cell carcinoma (85) and in pri- mary prostate cancer, as well as in prostate cancer metastatic to lymph nodes and bone (86). Figure 8 is a 11 C-acetate scan of a patient with prostate cancer metastatic to the spine. 18 F-fluorocholine (87) and 18 F-fluoroethylcholine (88) have significant urinary excretion, but are otherwise similar to 11 Ccholine. The short physical half-life of 11 C-labeled tracers (τ 1/2 = 20 min) limits their use to facilities possessing a cyclotron, and precludes production and transportation for multiple patient studies. The thrust of research with these tracers is to determine their clinical utility and then investigate longer-lived tracers, i.e. 18 F-labeled tracers with similar chemical properties.
Mandelkern and Raines
Amino Acid Tracers
Cellular proliferation is greater in most cancers than in normal tissues. While it requires the synthesis of proteins from amino acids, the synthetic rate is small and not practical as a source of contrast in imaging. However, many malignancies demonstrate increased transport of amino acids into cells, in analogy to increased glucose transport (89). Thus, intracellular accumulation of labeled amino acids is a possible strategy for imaging, especially if analogs that are accumulated but not metabolized can be found, again in analogy to FDG. 11 C-methionine PET is the best-studied amino acid tracer, especially for brain tumors. FDG uptake in brain tumors is correlated with the grade of malignancy (90), making lowand intermediate-grade tumors difficult to see against the high FDG uptake of normal cerebral cortex and subcortical structures. The uptake of 11 C-methionine reflects amino acid transport rather than protein synthesis. There is less of a correlation between tumor grade and 11 C-methionine uptake than for FDG, and less background tracer uptake, making detection of low-and intermediate-grade brain tumors superior. An example is shown in Figure 9 . 11 C-methionine has also been studied in prostate cancer (91), yielding in a small series a better sensitivity (72%) than that of FDG (48%), as well as in head and neck, breast, and lung cancers. However, 11 C-methionine has the disadvantage of a 11 C label, shows high uptake in liver, pancreas, and bowel, is excreted in the urine, and leads to recirculating labeled metabolites.
The best-studied 18 F-labeled amino acids are tyrosine analogs, namely L-2-18 F-fluorotyrosine, L-3-18 F-fluoro-αmethyl tyrosine (FMT), and O-(2-18 F-fluoroethyl)-L-tyrosine (FET) (89). These tracers also accumulate by virtue of increased transport rather than protein synthesis. In some lesions they accumulate in FDG-negative metastases, and may be useful in combination with FDG. 6-18 F dihydroxyphenylalanine (FDOPA), a tracer widely available for neuroimaging, also accumulates in some FDG-negative lesions.
Amino acid analogs, which are transported by specific systems but not metabolized, in analogy to FDG, have been studied. 11 C-α-aminoisobutyric acid (AIB) and 11 C-methyl α-aminoisobutyric acid (MeAIB) concentrate in cells via System A (alanine-preferring) transport, and concentration is related to cell growth. 18 F-1-amino-3-fluoromethylcyclobutance-1-carboxylic acid (FACBC) shows high tumor uptake and low background uptake in animal models.
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Nucleic Acid Tracers
Nucleic acids are incorporated into DNA in rapidly dividing cells. While thymidine is degraded rapidly in vivo, its analog 3´-deoxy-3´-fluorothymidine (FLT), an antiviral drug, is transported into cells, phosphorylated by thymidine kinase 1(TK1), and trapped, undergoing little degradation. Thus 18 F-FLT accumulation is a measure of the rate of cellular proliferation (92). TK1 activity increases about tenfold as cells enter the DNA synthetic phase. 18 F-FLT has been studied in solitary pulmonary nodules (93), yielding a sensitivity of 86% and a specificity of 100%. However, FLT is cleared by the urinary system, has high uptake in the liver and bone marrow, and does not cross the blood-brain barrier, limiting its utility. Figure 10 shows FLT accumulation in a primary lung cancer.
Hypoxia Tracers
Many tumors have hypoxic cells that can be resistant to both radiotherapy and chemotherapy. Hypoxia can potentially serve as a source of contrast in cancer imaging. Hypoxia imaging may assist treatment planning by identifying tissues that are candidates for treatment to overcome radiation resistance, or require additional radiation dose. Several nitroimidazole compounds, which bind to cellular macromolecules under hypoxic conditions, have been used. 18 F-fluoromisonidazole (FMISO) and 18 F-fluoroerythronitroimidazole (FETNIM) have been shown to concentrate in hypoxic regions of head and neck (94), lung, prostate, and brain tumors (95). For this purpose, hydrophilicity of the tracer is desirable since it increases the rate of elimination of the tracer from well-oxygenated tissues. Late imaging is required. For FET-NIM, 60 to 90 minutes is acceptable, but the maximum tumor to background ratio is achieved at greater than 180 minutes.
Tumor-specific (Oncotropic) Tracers
Rather than search for cancers with a non-specific tracer such as FDG, the use of tracers that bind to receptors specific to a cancer is potentially attractive. Non-specific tracers tend to be least sensitive in highly-differentiated lesions, such as neuroendocrine cancers, which are just those that retain specific characteristics. For example, functioning thyroid cancers that concentrate iodine are least likely to take up FDG and vice versa. Several types of oncotropic tracers are available: i. radiolabeled peptides and specific metabolic precursors, ii. neurotransmitter analogs, and iii. radiolabeled antibodies and antibody fragments.
Single-photon radiolabeled peptides have been developed, including octreotide (a long-acting analog ligand for somatostatin receptors, found in neuroendocrine and other tumors), and VIP (vasointestinal peptide, a ligand for receptors found in tumors of the GI tract, thyroid, breast, uterus, and bone. PET versions of these and other labeled peptides are being developed (96). The PET tracer 11 C-L-5-hydroxytryptophan (5HTP) is the labeled precursor of serotonin, and 6-18 F-dihydroxyphenylalanine (FDOPA) the labeled precursor of dopamine 123 Imetaiodobenzylguanidine (MIBG) and 6-18 F-fluorodopamine are substrates for the catecholamine uptake/storage system. These tracers are concentrated in neurotransmitter-producing tumor cells, such as carcinoid, pheochromocytoma, and neuroblastoma. 111 In-Capromab Pendetide (ProstaScint) is a whole murine antibody that is reactive with prostate specific membrane antigen (PSMA), a glycoprotein on the surface of normal and abnormal prostate epithelium. Strategies have been developed for enhancing ligand uptake in cancers.
Gene-expression Imaging
Gene expression can be imaged using a PET reporter gene, which codes for an enzyme or receptor that can be imaged using a PET tracer, and which can be introduced into the cell using a viral vector. For example, the herpes simplex 1 thymidine kinase (HSV1-TK) gene is imaged using labeled thymidine and acycloguanosine analogs, which are trapped in cells expressing the gene. The expression of the dopamine D2 receptor gene is imaged using 18 F-fluoroethylspiperone (FESP) or other high-affinity D2 ligands (97). If another gene, for example a therapeutic gene, is linked to the reporter gene, such that it is controlled by the same promotor, its expression can be inferred. This technique has potential for monitoring gene therapy, whether for cancer or other disorders. 
Conclusion
PET with FDG as a tracer for glucose metabolism is currently an effective and highly utilized tool for the diagnosis and management of cancer. As our clinical experience increases, we will obtain a better understanding of its applicability to different clinical problems. Continuing technological improvements in imaging, including higher resolution, better attenuation correction, and multimodality image registration, will further improve the efficacy of this method. The most significant improvements will come from the wide variety of tracers now being developed to image other metabolic pathways, and to identify cancer by specific biochemical, physiological, and genetic characteristics.
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